Business Standard

Wednesday, December 25, 2024 | 02:54 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Glenmark Pharma falls 3% as Baddi unit gets 7 observations from USFDA

The stock dipped 3% to Rs 574 on the BSE in intra-day trade.

Glenmark office
Premium

Glenmark office

SI Reporter Mumbai
Glenmark Pharmaceuticals dipped 3% to Rs 574 on the BSE in intra-day trade after the company said its Baddi unit gets seven observations from US health regulator.

“The US Food and Drug Administration (USFDA) issued seven observations through the form 483,” Glenmark Pharmaceuticals said in a regulatory filing.

The Baddi unit of Glenmark Pharmaceuticals underwent an US FDA audit from November 6, 2017 to November 11, 2017. The Baddi unit contributes approximately 10% of the revenue of US sales.

“We are in the midst of providing a comprehensive response to the observations and would be replying to

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in